Suppr超能文献

头孢托罗与A至D类分子的β-内酰胺酶的相互作用。

Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

作者信息

Queenan Anne Marie, Shang Wenchi, Kania Malgosia, Page Malcolm G P, Bush Karen

机构信息

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202 South, Raritan, NJ 08869, USA.

出版信息

Antimicrob Agents Chemother. 2007 Sep;51(9):3089-95. doi: 10.1128/AAC.00218-07. Epub 2007 Jun 25.

Abstract

The interactions of ceftobiprole with purified beta-lactamases from molecular classes A, B, C, and D were determined and compared with those of benzylpenicillin, cephaloridine, cefepime, and ceftazidime. Enzymes were selected from functional groups 1, 2a, 2b, 2be, 2d, 2e, and 3 to represent beta-lactamases from organisms within the antibacterial spectrum of ceftobiprole. Ceftobiprole was refractory to hydrolysis by the common staphylococcal PC1 beta-lactamase, the class A TEM-1 beta-lactamase, and the class C AmpC beta-lactamase but was labile to hydrolysis by class B, class D, and class A extended-spectrum beta-lactamases. Cefepime and ceftazidime followed similar patterns. In most cases, the hydrolytic stability of a substrate correlated with the MIC for the producing organism. Ceftobiprole and cefepime generally had lower MICs than ceftazidime for AmpC-producing organisms, particularly AmpC-overexpressing Enterobacter cloacae organisms. However, all three cephalosporins were hydrolyzed very slowly by AmpC cephalosporinases, suggesting that factors other than beta-lactamase stability contribute to lower ceftobiprole and cefepime MICs against many members of the family Enterobacteriaceae.

摘要

测定了头孢比普与A、B、C和D分子类别的纯化β-内酰胺酶之间的相互作用,并与苄青霉素、头孢啶、头孢吡肟和头孢他啶进行了比较。从功能组1、2a、2b、2be、2d、2e和3中选择酶来代表头孢比普抗菌谱内生物体的β-内酰胺酶。头孢比普对常见的葡萄球菌PC1β-内酰胺酶、A类TEM-1β-内酰胺酶和C类AmpCβ-内酰胺酶的水解具有抗性,但对B类、D类和A类超广谱β-内酰胺酶的水解不稳定。头孢吡肟和头孢他啶呈现类似模式。在大多数情况下,底物的水解稳定性与产生该酶的生物体的最低抑菌浓度(MIC)相关。对于产生AmpC酶的生物体,尤其是过表达AmpC的阴沟肠杆菌,头孢比普和头孢吡肟的MIC通常低于头孢他啶。然而,所有这三种头孢菌素被AmpC头孢菌素酶水解的速度都非常慢,这表明除β-内酰胺酶稳定性外,其他因素也导致头孢比普和头孢吡肟对许多肠杆菌科成员的MIC较低。

相似文献

1
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
Antimicrob Agents Chemother. 2007 Sep;51(9):3089-95. doi: 10.1128/AAC.00218-07. Epub 2007 Jun 25.
2
In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24. doi: 10.1111/j.1469-0691.2007.01722.x.
5
Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.
Antimicrob Agents Chemother. 1998 May;42(5):1168-75. doi: 10.1128/AAC.42.5.1168.
6
Naturally occurring extended-spectrum cephalosporinases in Escherichia coli.
Antimicrob Agents Chemother. 2006 Jul;50(7):2573-6. doi: 10.1128/AAC.01633-05.
7
Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
J Antimicrob Chemother. 2004 Dec;54(6):1130-3. doi: 10.1093/jac/dkh462. Epub 2004 Oct 14.
8
9
Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.
Antimicrob Agents Chemother. 1986 May;29(5):845-8. doi: 10.1128/AAC.29.5.845.

引用本文的文献

1
Structural comparison of substrate-binding pockets of serine β-lactamases in classes A, C, and D.
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2435365. doi: 10.1080/14756366.2024.2435365. Epub 2024 Dec 23.
2
Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria.
Antibiotics (Basel). 2024 Mar 15;13(3):260. doi: 10.3390/antibiotics13030260.
4
Bibliometric insights into the most influential papers on antibiotic adjuvants: a comprehensive analysis.
Front Pharmacol. 2023 Nov 13;14:1276018. doi: 10.3389/fphar.2023.1276018. eCollection 2023.
5
New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.
Pharmaceuticals (Basel). 2023 Sep 15;16(9):1304. doi: 10.3390/ph16091304.
6
Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains.
Nat Microbiol. 2023 Mar;8(3):410-423. doi: 10.1038/s41564-023-01320-2. Epub 2023 Feb 9.
7
Identification and metabolomic characterization of potent anti-MRSA phloroglucinol derivatives from Nakai (Polypodiaceae).
Front Pharmacol. 2022 Oct 20;13:961087. doi: 10.3389/fphar.2022.961087. eCollection 2022.
9
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
Paediatr Drugs. 2021 Sep;23(5):465-484. doi: 10.1007/s40272-021-00465-z. Epub 2021 Aug 26.
10
Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.
Int J Mol Sci. 2020 Nov 12;21(22):8527. doi: 10.3390/ijms21228527.

本文引用的文献

1
SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases.
Antimicrob Agents Chemother. 2006 Oct;50(10):3485-7. doi: 10.1128/AAC.00363-06.
4
Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia.
Diagn Microbiol Infect Dis. 2006 Aug;55(4):333-6. doi: 10.1016/j.diagmicrobio.2006.01.029. Epub 2006 May 2.
5
Diversity and evolution of blaZ from Staphylococcus aureus and coagulase-negative staphylococci.
J Antimicrob Chemother. 2006 Mar;57(3):450-60. doi: 10.1093/jac/dki492. Epub 2006 Jan 31.
6
OXA-type carbapenemases.
J Antimicrob Chemother. 2006 Mar;57(3):373-83. doi: 10.1093/jac/dki482. Epub 2006 Jan 30.
7
CTX-M-15 extended-spectrum (beta)-lactamase from Nigerian Klebsiella pneumoniae.
J Antimicrob Chemother. 2006 Jan;57(1):24-30. doi: 10.1093/jac/dki429. Epub 2005 Nov 30.
8
Extended-spectrum beta-lactamases: a clinical update.
Clin Microbiol Rev. 2005 Oct;18(4):657-86. doi: 10.1128/CMR.18.4.657-686.2005.
9
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
Antimicrob Agents Chemother. 2005 Oct;49(10):4210-9. doi: 10.1128/AAC.49.10.4210-4219.2005.
10
First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States.
Antimicrob Agents Chemother. 2005 Aug;49(8):3538-40. doi: 10.1128/AAC.49.8.3538-3540.2005.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验